Fig. 1: Patient disposition.
From: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Patient disposition for all 29 patients that were enrolled and received divarasib plus cetuximab.
Fig. 1: Patient disposition. | Nature Medicine
